Chapter 61 - Lupus Erythematosus Flashcards

1
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds

A

Malar rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions

A

Discoid rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation

A

Photosensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Oral or nasopharyngeal ulceration, usually painless, observed by a physician

A

Oral ulcers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Nonerosive arthritis involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion

A

Arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Serositis (2)

A

Pleuritis
Pericarditis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Convincing history of pleuritic pain or rub heard by a physician or evidence of pleural effusion

A

Pleuritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Documented by electrocardiogram or rub or evidence of pericardial effusion

A

Pericarditis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Renal disorder (2)

A

Persistent proteinuria
Cellular casts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Persistent proteinuria— ___ g/day or greater than ___ if quantitation not performed

A

Persistent proteinuria— >0.5 g/day or greater than 3+ if quantitation not performed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

May be red cell, hemoglobin, granular, tubular, or mixed

A

Cellular casts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Neurologic disorder (2)

A

Seizures
Psychosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Hematologic disorder (4)

A

Hemolytic anemia
Leukopenia
Lymphopenia
Thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Hemolytic anemia—with __________

A

Hemolytic anemia—with reticulocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Leukopenia— _____ μL total on ___ or more occasions

A

Leukopenia— <4000 μL total on 2 or more occasions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Lymphopenia— _____/μL on ___ or more occasions

A

Lymphopenia— <1500/μL on 2 or more occasions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Thrombocytopenia— _____ μL in the absence of offending drugs

A

Thrombocytopenia— <100,000 μL in the absence of offending drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Immunologic disorder (3)

A

Anti-DNA
Anti–Smith antigen
Positive finding of antiphospholipid antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

Positive finding of antiphospholipid antibodies based on

(1) an abnormal serum level of __________,

(2) a _____ test result for _____ using a standard method, or

(3) a _____ serologic test for _____ known to be _____ for at least _____ and confirmed by __________ or fluorescent treponemal antibody absorption test __________

A

Positive finding of antiphospholipid antibodies based on

(1) an abnormal serum level of immunoglobulin G or immunoglobulin M anticardiolipin antibodies,

(2) a positive test result for lupus anticoagulant using a standard method, or

(3) a false-positive serologic test for syphilis known to be positive for at least 6 months and confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

TABLE 61-2
The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus

An abnormal titer of __________ by immunofluorescence of an equivalent assay at any point in time and in the absence of drugs known to be associated with “drug-induced lupus” syndrome

A

An abnormal titer of antinuclear antibody by immunofluorescence of an equivalent assay at any point in time and in the absence of drugs known to be associated with “drug-induced lupus” syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

TABLE 61-6
Therapeutic Options for Lupus Erythematosus–Specific Skin Disease

First line vs Second line vs Short course only vs Third line vs Worth considering

Topical glucocorticoids

A

First line

22
Q

TABLE 61-6
Therapeutic Options for Lupus Erythematosus–Specific Skin Disease

First line vs Second line vs Short course only vs Third line vs Worth considering

Topical calcineurin inhibitor

A

First line

23
Q

TABLE 61-6
Therapeutic Options for Lupus Erythematosus–Specific Skin Disease

First line vs Second line vs Short course only vs Third line vs Worth considering

Intralesional triamcinolone acetonide

24
Q

TABLE 61-6
Therapeutic Options for Lupus Erythematosus–Specific Skin Disease

First line vs Second line vs Short course only vs Third line vs Worth considering

Hydroxychloroquine

A

Second line

25
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Chloroquine
Second line
26
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Quinacrine
Second line
27
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Prednisone
Short course only (2-16 weeks)
28
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Thalidomide
Short course only (2-16 weeks)
29
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Azathioprine
Third line (safer immunosuppressives)
30
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Mycophenolate mofetil
Third line (safer immunosuppressives)
31
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Methotrexate
Third line (safer immunosuppressives)
32
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Dapsone
Worth considering
33
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Accutane
Worth considering
34
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Acitretin
Worth considering
35
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease First line vs Second line vs Short course only vs Third line vs Worth considering Gold
Worth considering
36
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Topical glucocorticoids, topical calcineurin inhibitor
Class I topical steroid daily to twice daily for 2 weeks alternating with pimecrolimus 1% or tacrolimus 0.1% twice daily for 2 weeks
37
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Intralesional triamcinolone acetonide
Intralesional triamcinolone acetonide 2.5-10 mg/cc
38
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Hydroxychloroquine
Hydroxychloroquine 6.5 mg/kg/day based on ideal body weight
39
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Chloroquine
Chloroquine 3-3.5 mg/kg/day based on ideal body weight
40
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Quinacrine
Quinacrine 100 mg/day
41
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease Second line If monotherapy fails, add _____ to either _____ or _____
If monotherapy fails, add quinacrine to either hydroxychloroquine or chloroquine
42
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Prednisone
Prednisone 5-60 mg/day for 2-16 weeks
43
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Thalidomide
Thalidomide 50-200 mg/day; taper to 50 mg every other day on response for 2-16 weeks
44
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Azathioprine
Azathioprine 1.5-2.5 mg/kg/day
45
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Mycophenolate mofetil
Mycophenolate mofetil 1-1.5 g/dose, twice daily
46
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Methotrexate
Methotrexate 7.5-25 mg by mouth or subcutaneously, once weekly
47
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Dapsone
Dapsone 50-200 mg/day
48
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Accutane
Accutane 0.5-2 mg/kg/day
49
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Acitretin
Acitretin 10-50 mg/day
50
TABLE 61-6 Therapeutic Options for Lupus Erythematosus–Specific Skin Disease DOSE Gold
Gold titrate to 50 mg intramuscularly weekly, taper after 1 g